Physician profile
Aaron L Ellenbogen
NPI 1962472241
$1,562,747.46
in general payments reported to CMS, 2019-2025
73 companies · $276K in 2025
The $276K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $237K · 2020: $204K · 2021: $256K · 2022: $185K · 2023: $230K · 2024: $175K · 2025: $276K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $389K · Honoraria: $107K · Consulting Fee: $106K · Travel and Lodging: $57K · Food and Beverage: $16K · Education: $6,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $388,881.99 |
| Honoraria | $106,506.50 |
| Consulting Fee | $106,448.75 |
| Travel and Lodging | $57,013.63 |
| Food and Beverage | $15,690.86 |
| Education | $6,658.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $417,911.55 | 2019-2022 | |
| Abbvie INC. | $337,505.83 | 2021-2025 | |
| Mdd US Operations, LLC | $276,046.07 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Ipsen Biopharmaceuticals, INC | $157,922.06 | 2019-2025 | Dysport |
| Acorda Therapeutics, INC | $126,896.87 | 2019-2024 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $103,544.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Kyowa Kirin, INC. | $41,742.73 | 2020-2024 | Nourianz |
| Adamas Pharmaceuticals, INC. | $41,441.75 | 2019-2021 | |
| Tanabe Pharma America, INC. | $13,384.88 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $12,647.31 | 2024-2025 | Crexont, Ongentys, Rytary |
| Ipsen Innovation | $7,560.00 | 2024 | Dysport |
| Biohaven Pharmaceuticals, INC. | $5,177.26 | 2021 | |
| Azurity Pharmaceuticals, INC. | $4,275.00 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $3,509.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,365.80 | 2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $2,089.98 | 2019-2023 | Vyepti |
| Sage Therapeutics, LLC | $1,820.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $1,280.08 | 2025 | |
| Acadia Pharmaceuticals INC | $1,173.54 | 2019-2024 | Nuplazid |
| Abbott Laboratories | $964.34 | 2021-2023 | Infinity |
| Revance Therapeutics, INC. | $379.96 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $355.21 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $333.08 | 2022-2024 | Ingrezza, Ongentys |
| Merz North America, INC. | $222.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $212.50 | 2025 | |
| Emd Serono, INC. | $187.52 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $161.68 | 2021-2025 | Qelbree |
| Genentech USA, INC. | $147.28 | 2019-2024 | Enspryng, Ocrevus |
| Alexion Pharmaceuticals, INC. | $120.77 | 2019-2024 | Ultomiris |
| Ucb, INC. | $116.27 | 2020-2024 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $113.00 | 2022-2024 | Hyqvia |
| Celgene Corporation | $86.34 | 2022-2024 | Zeposia |
| Tg Therapeutics, INC. | $70.95 | 2023-2024 | |
| Philips North America LLC | $67.28 | 2024-2025 | (8874) Incourage, Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $61.95 | 2024 | |
| Eisai INC. | $59.84 | 2022-2024 | |
| Biogen, INC. | $59.00 | 2019-2024 | Spinraza |
| Amgen INC. | $56.53 | 2021 | |
| Merz Pharmaceuticals, LLC | $51.38 | 2021-2024 | Xeomin |
| Horizon Therapeutics Plc | $48.19 | 2022-2023 | Uplizna |
| Sumitomo Pharma America, INC. | $44.89 | 2024 | Aptiom |
| Sk Life Science, INC. | $42.46 | 2022-2023 | |
| Assertio Therapeutics, INC. | $41.74 | 2019-2020 | |
| Genzyme Corporation | $41.71 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $40.75 | 2024 | |
| Saol Therapeutics INC. | $39.05 | 2019 | |
| Grifols USA, LLC | $38.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.69 | 2022 | |
| Avion Pharmaceuticals | $30.00 | 2022-2023 | Dhivy |
| Medtronic, INC. | $21.85 | 2023 | Activa Pc |
| Octapharma USA, INC. | $20.03 | 2024 | Panzyga |
| Nevro Corp. | $19.43 | 2023 | Senza |
| Scilex Pharmaceuticals INC. | $18.57 | 2023 | Ztlido |
| Averitas Pharma INC. | $18.16 | 2024 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.69 | 2024 | Rexulti |
| Greenwich Biosciences, INC. | $17.59 | 2020 | |
| Argenx US, INC. | $17.12 | 2023 | Vyvgart |
| Corium, LLC | $15.87 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.19 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.57 | 2019 | |
| Hospira, INC. | $13.70 | 2024 | |
| Livanova USA, INC. | $11.92 | 2021 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$204,057.52 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ellenbogen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.